This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameOleandrin
Accession NumberDB12843
TypeSmall Molecule
GroupsExperimental
Description

Oleandrin has been used in trials studying the treatment of Lung Cancer and Chemotherapeutic Agent Toxicity.

Structure
Thumb
Synonyms
Anvirzel
Oleandrina
External IDs NSC-692219
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIII95UDU7I4
CAS number465-16-7
WeightAverage: 576.727
Monoisotopic: 576.329833126
Chemical FormulaC32H48O9
InChI KeyJLPDBLFIVFSOCC-XYXFTTADSA-N
InChI
InChI=1S/C32H48O9/c1-17-29(35)24(37-5)14-27(39-17)41-21-8-10-30(3)20(13-21)6-7-23-22(30)9-11-31(4)28(19-12-26(34)38-16-19)25(40-18(2)33)15-32(23,31)36/h12,17,20-25,27-29,35-36H,6-11,13-16H2,1-5H3/t17-,20+,21-,22-,23+,24-,25-,27-,28-,29-,30-,31+,32-/m0/s1
IUPAC Name
(1S,2S,5S,7R,10R,11S,13S,14R,15R)-11-hydroxy-5-{[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-2,15-dimethyl-14-(5-oxo-2,5-dihydrofuran-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl acetate
SMILES
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideAnvirzel may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-MethoxyestradiolAnvirzel may decrease the cardiotoxic activities of 2-Methoxyestradiol.Investigational
3-MethoxybenzamideAnvirzel may decrease the cardiotoxic activities of 3-Methoxybenzamide.Experimental
3,3'-diindolylmethaneAnvirzel may decrease the cardiotoxic activities of Diindolylmethane.Investigational
3,4-Dihydroxybenzoic AcidAnvirzel may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.Experimental
7-HydroxystaurosporineAnvirzel may decrease the cardiotoxic activities of 7-Hydroxystaurosporine.Experimental
8-azaguanineAnvirzel may decrease the cardiotoxic activities of 8-azaguanine.Experimental
9-aminocamptothecinAnvirzel may decrease the cardiotoxic activities of Aminocamptothecin.Investigational
AbirateroneAnvirzel may decrease the cardiotoxic activities of Abiraterone.Approved
AcebutololAcebutolol may increase the bradycardic activities of Anvirzel.Approved
AclarubicinAnvirzel may decrease the cardiotoxic activities of Aclarubicin.Investigational
ActeosideAnvirzel may decrease the cardiotoxic activities of Acteoside.Investigational
AfatinibAnvirzel may decrease the cardiotoxic activities of Afatinib.Approved
AfimoxifeneAnvirzel may decrease the cardiotoxic activities of Afimoxifene.Investigational
AfliberceptAnvirzel may decrease the cardiotoxic activities of Aflibercept.Approved
AlatrofloxacinAnvirzel may decrease the cardiotoxic activities of Alatrofloxacin.Withdrawn
AlbendazoleAnvirzel may decrease the cardiotoxic activities of Albendazole.Approved, Vet Approved
AldesleukinAnvirzel may decrease the cardiotoxic activities of Aldesleukin.Approved
AlemtuzumabAnvirzel may decrease the cardiotoxic activities of Alemtuzumab.Approved, Investigational
AlfacalcidolAlfacalcidol may increase the arrhythmogenic activities of Anvirzel.Approved, Nutraceutical
AlitretinoinAnvirzel may decrease the cardiotoxic activities of Alitretinoin.Approved, Investigational
AlprenololAlprenolol may increase the bradycardic activities of Anvirzel.Approved, Withdrawn
AltretamineAnvirzel may decrease the cardiotoxic activities of Altretamine.Approved
AlvocidibAnvirzel may decrease the cardiotoxic activities of Flavopiridol.Experimental, Investigational
AmikacinThe serum concentration of Anvirzel can be decreased when it is combined with Amikacin.Approved, Vet Approved
AmilorideThe therapeutic efficacy of Anvirzel can be decreased when used in combination with Amiloride.Approved
AminoglutethimideAnvirzel may decrease the cardiotoxic activities of Aminoglutethimide.Approved
Aminolevulinic acidAnvirzel may decrease the cardiotoxic activities of Aminolevulinic acid.Approved
AmiodaroneThe serum concentration of Anvirzel can be increased when it is combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Anvirzel can be increased when it is combined with Amodiaquine.Approved
AmonafideAnvirzel may decrease the cardiotoxic activities of Amonafide.Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Anvirzel.Approved, Investigational
AmrubicinAnvirzel may decrease the cardiotoxic activities of Amrubicin.Approved, Investigational
AmsacrineAnvirzel may decrease the cardiotoxic activities of Amsacrine.Approved
AnagrelideAnvirzel may decrease the cardiotoxic activities of Anagrelide.Approved
AnastrozoleAnvirzel may decrease the cardiotoxic activities of Anastrozole.Approved, Investigational
AnecortaveAnvirzel may decrease the cardiotoxic activities of Anecortave.Investigational
annamycinAnvirzel may decrease the cardiotoxic activities of annamycin.Investigational
AP 12009Anvirzel may decrease the cardiotoxic activities of AP 12009.Investigational
AP24534Anvirzel may decrease the cardiotoxic activities of AP24534.Investigational
ApaziquoneAnvirzel may decrease the cardiotoxic activities of Apaziquone.Investigational
ApramycinThe serum concentration of Anvirzel can be decreased when it is combined with Apramycin.Experimental, Vet Approved
ArbekacinThe serum concentration of Anvirzel can be decreased when it is combined with Arbekacin.Approved
ArotinololArotinolol may increase the bradycardic activities of Anvirzel.Approved
Arsenic trioxideAnvirzel may decrease the cardiotoxic activities of Arsenic trioxide.Approved, Investigational
AsparaginaseAnvirzel may decrease the cardiotoxic activities of Asparaginase.Approved
AtenololAtenolol may increase the bradycardic activities of Anvirzel.Approved
Atracurium besylateAtracurium besylate may increase the arrhythmogenic activities of Anvirzel.Approved
AxitinibAnvirzel may decrease the cardiotoxic activities of Axitinib.Approved, Investigational
AzacitidineAnvirzel may decrease the cardiotoxic activities of Azacitidine.Approved, Investigational
AzathioprineAnvirzel may decrease the cardiotoxic activities of Azathioprine.Approved
AZD-4547Anvirzel may decrease the cardiotoxic activities of Azd4547.Investigational
Azelaic AcidAnvirzel may decrease the cardiotoxic activities of Azelaic Acid.Approved
AzithromycinThe serum concentration of Anvirzel can be increased when it is combined with Azithromycin.Approved
BalsalazideThe serum concentration of Anvirzel can be decreased when it is combined with Balsalazide.Approved, Investigational
BatimastatAnvirzel may decrease the cardiotoxic activities of Batimastat.Experimental
BefunololBefunolol may increase the bradycardic activities of Anvirzel.Experimental
BelinostatAnvirzel may decrease the cardiotoxic activities of Belinostat.Approved, Investigational
BelotecanAnvirzel may decrease the cardiotoxic activities of Belotecan.Investigational
BendamustineAnvirzel may decrease the cardiotoxic activities of Bendamustine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Anvirzel.Approved
BesifloxacinAnvirzel may decrease the cardiotoxic activities of Besifloxacin.Approved
BetaxololBetaxolol may increase the bradycardic activities of Anvirzel.Approved
Betulinic AcidAnvirzel may decrease the cardiotoxic activities of Betulinic Acid.Investigational
BevacizumabAnvirzel may decrease the cardiotoxic activities of Bevacizumab.Approved, Investigational
BevantololBevantolol may increase the bradycardic activities of Anvirzel.Approved
BexaroteneAnvirzel may decrease the cardiotoxic activities of Bexarotene.Approved, Investigational
BicalutamideAnvirzel may decrease the cardiotoxic activities of Bicalutamide.Approved
BinetrakinAnvirzel may decrease the cardiotoxic activities of Il 4.Investigational
BisoprololBisoprolol may increase the bradycardic activities of Anvirzel.Approved
BizelesinAnvirzel may decrease the cardiotoxic activities of Bizelesin.Investigational
BleomycinAnvirzel may decrease the cardiotoxic activities of Bleomycin.Approved
BlinatumomabAnvirzel may decrease the cardiotoxic activities of Blinatumomab.Approved
BopindololBopindolol may increase the bradycardic activities of Anvirzel.Approved
BortezomibAnvirzel may decrease the cardiotoxic activities of Bortezomib.Approved, Investigational
BosutinibAnvirzel may decrease the cardiotoxic activities of Bosutinib.Approved
Brentuximab vedotinAnvirzel may decrease the cardiotoxic activities of Brentuximab vedotin.Approved
BroxuridineAnvirzel may decrease the cardiotoxic activities of Broxuridine.Investigational
Bryostatin 1Anvirzel may decrease the cardiotoxic activities of Bryostatin 1.Investigational
BSI-201Anvirzel may decrease the cardiotoxic activities of BSI-201.Investigational
BucindololBucindolol may increase the bradycardic activities of Anvirzel.Investigational
BufuralolBufuralol may increase the bradycardic activities of Anvirzel.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Anvirzel.Approved
BupranololBupranolol may increase the bradycardic activities of Anvirzel.Approved
BusulfanAnvirzel may decrease the cardiotoxic activities of Busulfan.Approved, Investigational
Buthionine SulfoximineAnvirzel may decrease the cardiotoxic activities of Buthionine Sulfoximine.Investigational
CabazitaxelAnvirzel may decrease the cardiotoxic activities of Cabazitaxel.Approved
CabergolineAnvirzel may decrease the cardiotoxic activities of Cabergoline.Approved
CabozantinibAnvirzel may decrease the cardiotoxic activities of Cabozantinib.Approved
CalcidiolCalcidiol may increase the arrhythmogenic activities of Anvirzel.Approved, Nutraceutical
CalcipotriolAnvirzel may decrease the cardiotoxic activities of Calcipotriol.Approved
CalcitriolCalcitriol may increase the arrhythmogenic activities of Anvirzel.Approved, Nutraceutical
CalciumCalcium may increase the arrhythmogenic activities of Anvirzel.Nutraceutical
Calcium AcetateCalcium Acetate may increase the arrhythmogenic activities of Anvirzel.Approved
Calcium CarbonateCalcium carbonate may increase the arrhythmogenic activities of Anvirzel.Approved
Calcium ChlorideCalcium Chloride may increase the arrhythmogenic activities of Anvirzel.Approved
Calcium CitrateCalcium citrate may increase the arrhythmogenic activities of Anvirzel.Approved
Calcium glubionateCalcium glubionate may increase the arrhythmogenic activities of Anvirzel.Approved
Calcium GluceptateCalcium Gluceptate may increase the arrhythmogenic activities of Anvirzel.Approved
Calcium gluconateCalcium gluconate may increase the arrhythmogenic activities of Anvirzel.Approved, Vet Approved
CamptothecinAnvirzel may decrease the cardiotoxic activities of Camptothecin.Experimental
CapecitabineAnvirzel may decrease the cardiotoxic activities of Capecitabine.Approved, Investigational
CarbimazoleThe serum concentration of Anvirzel can be increased when it is combined with Carbimazole.Approved
CarbomycinThe serum concentration of Anvirzel can be increased when it is combined with Carbomycin.Vet Approved
CarboplatinAnvirzel may decrease the cardiotoxic activities of Carboplatin.Approved
Carbopol 974PAnvirzel may decrease the cardiotoxic activities of polyacrylic acid.Investigational
CarboxyamidotriazoleAnvirzel may decrease the cardiotoxic activities of Cai.Investigational
CarfilzomibAnvirzel may decrease the cardiotoxic activities of Carfilzomib.Approved
CarmofurAnvirzel may decrease the cardiotoxic activities of Carmofur.Withdrawn
CarmustineAnvirzel may decrease the cardiotoxic activities of Carmustine.Approved
CarteololCarteolol may increase the bradycardic activities of Anvirzel.Approved
CarvedilolCarvedilol may increase the bradycardic activities of Anvirzel.Approved, Investigational
CatumaxomabAnvirzel may decrease the cardiotoxic activities of Catumaxomab.Investigational
CediranibAnvirzel may decrease the cardiotoxic activities of AZD2171.Investigational
CelecoxibAnvirzel may decrease the cardiotoxic activities of Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the bradycardic activities of Anvirzel.Approved, Investigational
CeritinibAnvirzel may decrease the cardiotoxic activities of Ceritinib.Approved
CetuximabAnvirzel may decrease the cardiotoxic activities of Cetuximab.Approved
ChlorambucilAnvirzel may decrease the cardiotoxic activities of Chlorambucil.Approved
ChloroquineThe serum concentration of Anvirzel can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Anvirzel.Approved, Vet Approved
ChlorotrianiseneAnvirzel may decrease the cardiotoxic activities of Chlorotrianisene.Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Anvirzel.Approved
CholecalciferolCholecalciferol may increase the arrhythmogenic activities of Anvirzel.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Anvirzel resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinAnvirzel may decrease the cardiotoxic activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinAnvirzel may decrease the cardiotoxic activities of Ciprofloxacin.Approved, Investigational
Cisatracurium besylateCisatracurium besylate may increase the arrhythmogenic activities of Anvirzel.Approved
CisplatinAnvirzel may decrease the cardiotoxic activities of Cisplatin.Approved
CladribineAnvirzel may decrease the cardiotoxic activities of Cladribine.Approved, Investigational
ClarithromycinThe serum concentration of Anvirzel can be increased when it is combined with Clarithromycin.Approved
ClofarabineAnvirzel may decrease the cardiotoxic activities of Clofarabine.Approved, Investigational
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Anvirzel.Approved
ColchicineAnvirzel may decrease the cardiotoxic activities of Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Anvirzel resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Anvirzel resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CordycepinAnvirzel may decrease the cardiotoxic activities of Cordycepin.Investigational
CrenolanibAnvirzel may decrease the cardiotoxic activities of Crenolanib.Investigational
CrizotinibAnvirzel may decrease the cardiotoxic activities of Crizotinib.Approved
CurcuminAnvirzel may decrease the cardiotoxic activities of Curcumin.Investigational
CyclophosphamideAnvirzel may decrease the cardiotoxic activities of Cyclophosphamide.Approved, Investigational
Cyproterone acetateAnvirzel may decrease the cardiotoxic activities of Cyproterone acetate.Approved, Investigational
CytarabineAnvirzel may decrease the cardiotoxic activities of Cytarabine.Approved, Investigational
DabrafenibAnvirzel may decrease the cardiotoxic activities of Dabrafenib.Approved
DacarbazineAnvirzel may decrease the cardiotoxic activities of Dacarbazine.Approved, Investigational
DactinomycinAnvirzel may decrease the cardiotoxic activities of Dactinomycin.Approved
DaratumumabAnvirzel may decrease the cardiotoxic activities of Daratumumab.Approved
DasatinibAnvirzel may decrease the cardiotoxic activities of Dasatinib.Approved, Investigational
DaunorubicinAnvirzel may decrease the cardiotoxic activities of Daunorubicin.Approved
DecamethoniumDecamethonium may increase the arrhythmogenic activities of Anvirzel.Approved
DecitabineAnvirzel may decrease the cardiotoxic activities of Decitabine.Approved, Investigational
Denileukin diftitoxAnvirzel may decrease the cardiotoxic activities of Denileukin diftitox.Approved, Investigational
DeoxyspergualinAnvirzel may decrease the cardiotoxic activities of Deoxyspergualin.Investigational
DexamethasoneAnvirzel may decrease the cardiotoxic activities of Dexamethasone.Approved, Investigational, Vet Approved
DexrazoxaneAnvirzel may decrease the cardiotoxic activities of Dexrazoxane.Approved, Withdrawn
DianhydrogalactitolAnvirzel may decrease the cardiotoxic activities of Val 083.Investigational
DienogestAnvirzel may decrease the cardiotoxic activities of Dienogest.Approved
DiethylstilbestrolAnvirzel may decrease the cardiotoxic activities of Diethylstilbestrol.Approved
DihydrostreptomycinThe serum concentration of Anvirzel can be decreased when it is combined with Dihydrostreptomycin.Vet Approved
DihydrotachysterolDihydrotachysterol may increase the arrhythmogenic activities of Anvirzel.Approved
DiltiazemDiltiazem may increase the atrioventricular blocking (AV block) activities of Anvirzel.Approved
DinutuximabAnvirzel may decrease the cardiotoxic activities of Dinutuximab.Approved
DocetaxelAnvirzel may decrease the cardiotoxic activities of Docetaxel.Approved, Investigational
Domoic AcidDomoic Acid may increase the arrhythmogenic activities of Anvirzel.Experimental
Doxacurium chlorideDoxacurium chloride may increase the arrhythmogenic activities of Anvirzel.Approved
DoxercalciferolDoxercalciferol may increase the arrhythmogenic activities of Anvirzel.Approved
DoxifluridineAnvirzel may decrease the cardiotoxic activities of Doxifluridine.Investigational
DoxorubicinAnvirzel may decrease the cardiotoxic activities of Doxorubicin.Approved, Investigational
EcabetAnvirzel may decrease the cardiotoxic activities of Ecabet.Approved, Investigational
EdrophoniumEdrophonium may increase the atrioventricular blocking (AV block) activities of Anvirzel.Approved
EflornithineAnvirzel may decrease the cardiotoxic activities of Eflornithine.Approved, Withdrawn
EG009Anvirzel may decrease the cardiotoxic activities of EG009.Investigational
ElsamitrucinAnvirzel may decrease the cardiotoxic activities of Elsamitrucin.Investigational
EndostatinAnvirzel may decrease the cardiotoxic activities of Endostatin.Investigational
EnoxacinAnvirzel may decrease the cardiotoxic activities of Enoxacin.Approved
EnrofloxacinAnvirzel may decrease the cardiotoxic activities of Enrofloxacin.Vet Approved
EntinostatAnvirzel may decrease the cardiotoxic activities of Entinostat.Investigational
EpirubicinAnvirzel may decrease the cardiotoxic activities of Epirubicin.Approved
EplerenoneThe therapeutic efficacy of Anvirzel can be decreased when used in combination with Eplerenone.Approved
EpofolateAnvirzel may decrease the cardiotoxic activities of Epofolate.Investigational
ErgocalciferolErgocalciferol may increase the arrhythmogenic activities of Anvirzel.Approved, Nutraceutical
EribulinAnvirzel may decrease the cardiotoxic activities of Eribulin.Approved, Investigational
ErlotinibAnvirzel may decrease the cardiotoxic activities of Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Anvirzel can be increased when it is combined with Erythromycin.Approved, Vet Approved
EsmololEsmolol may increase the bradycardic activities of Anvirzel.Approved
EstramustineAnvirzel may decrease the cardiotoxic activities of Estramustine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Anvirzel.Approved
EtanidazoleAnvirzel may decrease the cardiotoxic activities of Etanidazole.Investigational
Ethiodized oilAnvirzel may decrease the cardiotoxic activities of Ethiodized oil.Approved
Ethyl carbamateAnvirzel may decrease the cardiotoxic activities of Ethyl carbamate.Withdrawn
EtoposideAnvirzel may decrease the cardiotoxic activities of Etoposide.Approved
EverolimusAnvirzel may decrease the cardiotoxic activities of Everolimus.Approved
ExatecanAnvirzel may decrease the cardiotoxic activities of Exatecan.Investigational
ExemestaneAnvirzel may decrease the cardiotoxic activities of Exemestane.Approved, Investigational
exisulindAnvirzel may decrease the cardiotoxic activities of exisulind.Investigational
FenretinideAnvirzel may decrease the cardiotoxic activities of Fenretinide.Investigational
FiacitabineAnvirzel may decrease the cardiotoxic activities of Fiacitabine.Investigational
FleroxacinAnvirzel may decrease the cardiotoxic activities of Fleroxacin.Approved
FloxuridineAnvirzel may decrease the cardiotoxic activities of Floxuridine.Approved
FludarabineAnvirzel may decrease the cardiotoxic activities of Fludarabine.Approved
FlumequineAnvirzel may decrease the cardiotoxic activities of Flumequine.Withdrawn
FluorouracilAnvirzel may decrease the cardiotoxic activities of Fluorouracil.Approved
FlutamideAnvirzel may decrease the cardiotoxic activities of Flutamide.Approved
FormestaneAnvirzel may decrease the cardiotoxic activities of Formestane.Approved, Investigational, Withdrawn
FormycinAnvirzel may decrease the cardiotoxic activities of Formycin.Experimental
FotemustineAnvirzel may decrease the cardiotoxic activities of Fotemustine.Experimental
FramycetinThe serum concentration of Anvirzel can be decreased when it is combined with Framycetin.Approved
FulvestrantAnvirzel may decrease the cardiotoxic activities of Fulvestrant.Approved, Investigational
FumagillinAnvirzel may decrease the cardiotoxic activities of Fumagillin.Experimental
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Anvirzel.Approved, Vet Approved
Gallamine TriethiodideGallamine Triethiodide may increase the arrhythmogenic activities of Anvirzel.Approved
Gallium nitrateAnvirzel may decrease the cardiotoxic activities of Gallium nitrate.Approved, Investigational
GarenoxacinAnvirzel may decrease the cardiotoxic activities of Garenoxacin.Investigational
GatifloxacinAnvirzel may decrease the cardiotoxic activities of Gatifloxacin.Approved, Investigational
GefitinibAnvirzel may decrease the cardiotoxic activities of Gefitinib.Approved, Investigational
GeldanamycinAnvirzel may decrease the cardiotoxic activities of Geldanamycin.Experimental
GemcitabineAnvirzel may decrease the cardiotoxic activities of Gemcitabine.Approved
GemifloxacinAnvirzel may decrease the cardiotoxic activities of Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinAnvirzel may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.Approved
GeneticinThe serum concentration of Anvirzel can be decreased when it is combined with Geneticin.Experimental
GenisteinAnvirzel may decrease the cardiotoxic activities of Genistein.Investigational
GentamicinThe serum concentration of Anvirzel can be decreased when it is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of Anvirzel can be decreased when it is combined with GENTAMICIN C1A.Experimental
Ginsenoside CAnvirzel may decrease the cardiotoxic activities of Ginsenoside C.Nutraceutical
GoserelinAnvirzel may decrease the cardiotoxic activities of Goserelin.Approved
GrepafloxacinAnvirzel may decrease the cardiotoxic activities of Grepafloxacin.Withdrawn
GS 0573Anvirzel may decrease the cardiotoxic activities of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.Investigational
GusperimusAnvirzel may decrease the cardiotoxic activities of Gusperimus.Investigational
HadacidinAnvirzel may decrease the cardiotoxic activities of Hadacidin.Experimental
HalofuginoneAnvirzel may decrease the cardiotoxic activities of Halofuginone.Investigational, Vet Approved
HexestrolAnvirzel may decrease the cardiotoxic activities of Hexestrol.Withdrawn
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Anvirzel.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Anvirzel.Approved
HydroxychloroquineThe serum concentration of Anvirzel can be increased when it is combined with Hydroxychloroquine.Approved
Hydroxyprogesterone caproateAnvirzel may decrease the cardiotoxic activities of Hydroxyprogesterone caproate.Approved
HydroxyureaAnvirzel may decrease the cardiotoxic activities of Hydroxyurea.Approved
Hygromycin BThe serum concentration of Anvirzel can be decreased when it is combined with Hygromycin B.Vet Approved
IbrutinibAnvirzel may decrease the cardiotoxic activities of Ibrutinib.Approved
IdarubicinAnvirzel may decrease the cardiotoxic activities of Idarubicin.Approved
IdelalisibAnvirzel may decrease the cardiotoxic activities of Idelalisib.Approved
IfosfamideAnvirzel may decrease the cardiotoxic activities of Ifosfamide.Approved
ImatinibAnvirzel may decrease the cardiotoxic activities of Imatinib.Approved
ImiquimodAnvirzel may decrease the cardiotoxic activities of Imiquimod.Approved, Investigational
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Anvirzel.Approved
IndenololIndenolol may increase the bradycardic activities of Anvirzel.Withdrawn
IndirubinAnvirzel may decrease the cardiotoxic activities of Indirubin.Investigational
InfigratinibAnvirzel may decrease the cardiotoxic activities of Bgj398.Investigational
INNO-206The serum concentration of Anvirzel can be decreased when it is combined with INNO-206.Investigational
Interferon beta-1aAnvirzel may decrease the cardiotoxic activities of Interferon beta-1a.Approved, Investigational
Interferon beta-1bAnvirzel may decrease the cardiotoxic activities of Interferon beta-1b.Approved
IobenguaneAnvirzel may decrease the cardiotoxic activities of Iobenguane.Approved
IpilimumabAnvirzel may decrease the cardiotoxic activities of Ipilimumab.Approved
IrinotecanAnvirzel may decrease the cardiotoxic activities of Irinotecan.Approved, Investigational
IrofulvenAnvirzel may decrease the cardiotoxic activities of MGI-114.Investigational
ItraconazoleThe serum concentration of Anvirzel can be increased when it is combined with Itraconazole.Approved, Investigational
IxabepiloneAnvirzel may decrease the cardiotoxic activities of Ixabepilone.Approved, Investigational
IxazomibAnvirzel may decrease the cardiotoxic activities of Ixazomib.Approved
JosamycinThe serum concentration of Anvirzel can be increased when it is combined with Josamycin.Approved
KanamycinThe serum concentration of Anvirzel can be decreased when it is combined with Kanamycin.Approved, Vet Approved
KaolinThe serum concentration of Anvirzel can be decreased when it is combined with Kaolin.Approved
KitasamycinThe serum concentration of Anvirzel can be increased when it is combined with Kitasamycin.Experimental
KOS-1584Anvirzel may decrease the cardiotoxic activities of KOS-1584.Investigational
L-alanosineAnvirzel may decrease the cardiotoxic activities of L-alanosine.Investigational
L-EflornithineAnvirzel may decrease the cardiotoxic activities of Alpha-Difluoromethylornithine.Experimental
LabetalolLabetalol may increase the bradycardic activities of Anvirzel.Approved
LandiololAop200704 may increase the bradycardic activities of Anvirzel.Investigational
LanreotideAnvirzel may decrease the cardiotoxic activities of Lanreotide.Approved
LapatinibAnvirzel may decrease the cardiotoxic activities of Lapatinib.Approved, Investigational
LeflunomideAnvirzel may decrease the cardiotoxic activities of Leflunomide.Approved, Investigational
LenalidomideAnvirzel may decrease the cardiotoxic activities of Lenalidomide.Approved
LenvatinibAnvirzel may decrease the cardiotoxic activities of Lenvatinib.Approved
LetrozoleAnvirzel may decrease the cardiotoxic activities of Letrozole.Approved, Investigational
LeuprolideAnvirzel may decrease the cardiotoxic activities of Leuprolide.Approved, Investigational
LevobunololLevobunolol may increase the bradycardic activities of Anvirzel.Approved
LevofloxacinAnvirzel may decrease the cardiotoxic activities of Levofloxacin.Approved, Investigational
LiarozoleAnvirzel may decrease the cardiotoxic activities of Liarozole.Investigational
LicoriceThe risk or severity of adverse effects can be increased when Licorice is combined with Anvirzel.Approved
LomefloxacinAnvirzel may decrease the cardiotoxic activities of Lomefloxacin.Approved
LomustineAnvirzel may decrease the cardiotoxic activities of Lomustine.Approved
LonidamineAnvirzel may decrease the cardiotoxic activities of Lonidamine.Approved, Investigational
LycopeneAnvirzel may decrease the cardiotoxic activities of Lycopene.Approved
MafosfamideAnvirzel may decrease the cardiotoxic activities of Mafosfamide.Investigational
MasitinibAnvirzel may decrease the cardiotoxic activities of Masitinib.Vet Approved
MasoprocolAnvirzel may decrease the cardiotoxic activities of Masoprocol.Approved
MaxacalcitolAnvirzel may decrease the cardiotoxic activities of Maxacalcitol.Approved
MebendazoleAnvirzel may decrease the cardiotoxic activities of Mebendazole.Approved, Vet Approved
MechlorethamineAnvirzel may decrease the cardiotoxic activities of Mechlorethamine.Approved
MedrogestoneAnvirzel may decrease the cardiotoxic activities of Medrogestone.Approved
Medroxyprogesterone acetateAnvirzel may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateAnvirzel may decrease the cardiotoxic activities of Megestrol acetate.Approved, Vet Approved
MelphalanAnvirzel may decrease the cardiotoxic activities of Melphalan.Approved
MequinolAnvirzel may decrease the cardiotoxic activities of Mequinol.Approved
MercaptopurineAnvirzel may decrease the cardiotoxic activities of Mercaptopurine.Approved
MerestinibAnvirzel may decrease the cardiotoxic activities of Ly2801653.Investigational
MesalazineThe serum concentration of Anvirzel can be decreased when it is combined with Mesalazine.Approved
MethimazoleThe serum concentration of Anvirzel can be increased when it is combined with Methimazole.Approved
MethotrexateAnvirzel may decrease the cardiotoxic activities of Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Anvirzel.Approved
Methyl aminolevulinateAnvirzel may decrease the cardiotoxic activities of Methyl aminolevulinate.Approved
MethylprednisoloneAnvirzel may decrease the cardiotoxic activities of Methylprednisolone.Approved, Vet Approved
MethyltestosteroneAnvirzel may decrease the cardiotoxic activities of Methyltestosterone.Approved
MetipranololMetipranolol may increase the bradycardic activities of Anvirzel.Approved
MetocurineMetocurine may increase the arrhythmogenic activities of Anvirzel.Approved
Metocurine IodideMetocurine Iodide may increase the arrhythmogenic activities of Anvirzel.Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Anvirzel.Approved
MetoprololMetoprolol may increase the bradycardic activities of Anvirzel.Approved, Investigational
MetrizamideThe serum concentration of Anvirzel can be decreased when it is combined with Metrizamide.Approved
MidodrineAnvirzel may increase the bradycardic activities of Midodrine.Approved
MidostaurinAnvirzel may decrease the cardiotoxic activities of Midostaurin.Approved
MiltefosineAnvirzel may decrease the cardiotoxic activities of Miltefosine.Approved
MisonidazoleAnvirzel may decrease the cardiotoxic activities of Misonidazole.Investigational
MitoguazoneAnvirzel may decrease the cardiotoxic activities of Mitoguazone.Investigational
MitolactolAnvirzel may decrease the cardiotoxic activities of Mitolactol.Investigational
MitomycinAnvirzel may decrease the cardiotoxic activities of Mitomycin.Approved
MitotaneAnvirzel may decrease the cardiotoxic activities of Mitotane.Approved
MitoxantroneAnvirzel may decrease the cardiotoxic activities of Mitoxantrone.Approved, Investigational
MivacuriumMivacurium may increase the arrhythmogenic activities of Anvirzel.Approved
MizoribineAnvirzel may decrease the cardiotoxic activities of Mizoribine.Investigational
MLN576Anvirzel may decrease the cardiotoxic activities of MLN576.Investigational
MolgramostimAnvirzel may decrease the cardiotoxic activities of Molgramostim.Investigational
motexafin gadoliniumAnvirzel may decrease the cardiotoxic activities of motexafin gadolinium.Investigational
MoxifloxacinAnvirzel may decrease the cardiotoxic activities of Moxifloxacin.Approved, Investigational
Mycophenolic acidAnvirzel may decrease the cardiotoxic activities of Mycophenolic acid.Approved
NadololNadolol may increase the bradycardic activities of Anvirzel.Approved
Nalidixic AcidAnvirzel may decrease the cardiotoxic activities of Nalidixic Acid.Approved
NamitecanAnvirzel may decrease the cardiotoxic activities of Namitecan.Investigational
NavitoclaxAnvirzel may decrease the cardiotoxic activities of Navitoclax.Investigational
NeamineThe serum concentration of Anvirzel can be decreased when it is combined with Neamine.Experimental
NebularineAnvirzel may decrease the cardiotoxic activities of Purine Riboside.Experimental
NecitumumabAnvirzel may decrease the cardiotoxic activities of Necitumumab.Approved
NelarabineAnvirzel may decrease the cardiotoxic activities of Nelarabine.Approved, Investigational
NeomycinThe serum concentration of Anvirzel can be decreased when it is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinNeosaxitoxin may increase the arrhythmogenic activities of Anvirzel.Investigational
NetilmicinThe serum concentration of Anvirzel can be decreased when it is combined with Netilmicin.Approved
NiguldipineAnvirzel may decrease the cardiotoxic activities of Niguldipine.Experimental
NilotinibAnvirzel may decrease the cardiotoxic activities of Nilotinib.Approved, Investigational
NilutamideAnvirzel may decrease the cardiotoxic activities of Nilutamide.Approved
NimustineAnvirzel may decrease the cardiotoxic activities of Nimustine.Investigational
NintedanibAnvirzel may decrease the cardiotoxic activities of Nintedanib.Approved
NivolumabAnvirzel may decrease the cardiotoxic activities of Nivolumab.Approved
nocodazoleAnvirzel may decrease the cardiotoxic activities of nocodazole.Experimental
NolatrexedAnvirzel may decrease the cardiotoxic activities of Nolatrexed.Investigational
NorfloxacinAnvirzel may decrease the cardiotoxic activities of Norfloxacin.Approved
ObinutuzumabAnvirzel may decrease the cardiotoxic activities of Obinutuzumab.Approved
OctreotideAnvirzel may decrease the cardiotoxic activities of Octreotide.Approved, Investigational
OfatumumabAnvirzel may decrease the cardiotoxic activities of Ofatumumab.Approved
OfloxacinAnvirzel may decrease the cardiotoxic activities of Ofloxacin.Approved
OlaparibAnvirzel may decrease the cardiotoxic activities of Olaparib.Approved
OleandomycinThe serum concentration of Anvirzel can be increased when it is combined with Oleandomycin.Vet Approved
OlsalazineThe serum concentration of Anvirzel can be decreased when it is combined with Olsalazine.Approved
Omacetaxine mepesuccinateAnvirzel may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.Approved
OprelvekinAnvirzel may decrease the cardiotoxic activities of Oprelvekin.Approved, Investigational
OsimertinibAnvirzel may decrease the cardiotoxic activities of Osimertinib.Approved
OxaliplatinAnvirzel may decrease the cardiotoxic activities of Oxaliplatin.Approved, Investigational
OxprenololOxprenolol may increase the bradycardic activities of Anvirzel.Approved
PaclitaxelAnvirzel may decrease the cardiotoxic activities of Paclitaxel.Approved, Vet Approved
PalbociclibAnvirzel may decrease the cardiotoxic activities of Palbociclib.Approved
PalifosfamideAnvirzel may decrease the cardiotoxic activities of Palifosfamide.Investigational
PamidronateAnvirzel may decrease the cardiotoxic activities of Pamidronate.Approved
PancuroniumPancuronium may increase the arrhythmogenic activities of Anvirzel.Approved
PanitumumabAnvirzel may decrease the cardiotoxic activities of Panitumumab.Approved, Investigational
PanobinostatAnvirzel may decrease the cardiotoxic activities of Panobinostat.Approved, Investigational
Parathyroid hormoneThe risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Anvirzel.Approved, Investigational
ParicalcitolParicalcitol may increase the arrhythmogenic activities of Anvirzel.Approved, Investigational
ParomomycinThe serum concentration of Anvirzel can be decreased when it is combined with Paromomycin.Approved, Investigational
PatupiloneAnvirzel may decrease the cardiotoxic activities of Epothilone B.Experimental, Investigational
PazopanibAnvirzel may decrease the cardiotoxic activities of Pazopanib.Approved
PazufloxacinAnvirzel may decrease the cardiotoxic activities of Pazufloxacin.Investigational
PefloxacinAnvirzel may decrease the cardiotoxic activities of Pefloxacin.Approved
PegaspargaseAnvirzel may decrease the cardiotoxic activities of Pegaspargase.Approved, Investigational
PembrolizumabAnvirzel may decrease the cardiotoxic activities of Pembrolizumab.Approved
PemetrexedAnvirzel may decrease the cardiotoxic activities of Pemetrexed.Approved, Investigational
PenbutololPenbutolol may increase the bradycardic activities of Anvirzel.Approved, Investigational
PenclomedineAnvirzel may decrease the cardiotoxic activities of Penclomedine.Investigational
PentostatinAnvirzel may decrease the cardiotoxic activities of Pentostatin.Approved, Investigational
PertuzumabAnvirzel may decrease the cardiotoxic activities of Pertuzumab.Approved
Phenylacetic acidAnvirzel may decrease the cardiotoxic activities of Phenylacetic acid.Approved
Phenylbutyric acidAnvirzel may decrease the cardiotoxic activities of Sodium phenylbutyrate.Approved, Investigational
PindololPindolol may increase the bradycardic activities of Anvirzel.Approved
PipecuroniumPipecuronium may increase the arrhythmogenic activities of Anvirzel.Approved
PipobromanAnvirzel may decrease the cardiotoxic activities of Pipobroman.Approved
PirarubicinAnvirzel may decrease the cardiotoxic activities of Pirarubicin.Investigational
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Anvirzel.Experimental
PirfenidoneAnvirzel may decrease the cardiotoxic activities of Pirfenidone.Investigational
PirlindoleAnvirzel may decrease the cardiotoxic activities of Pirlindole.Approved
PixantroneAnvirzel may decrease the cardiotoxic activities of Pixantrone.Investigational
PlevitrexedAnvirzel may decrease the cardiotoxic activities of Plevitrexed.Investigational
PlicamycinAnvirzel may decrease the cardiotoxic activities of Plicamycin.Approved, Withdrawn
PodofiloxAnvirzel may decrease the cardiotoxic activities of Podofilox.Approved
PodophyllinAnvirzel may decrease the cardiotoxic activities of Podophyllin.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Anvirzel.Approved
PomalidomideAnvirzel may decrease the cardiotoxic activities of Pomalidomide.Approved
PonatinibAnvirzel may decrease the cardiotoxic activities of Ponatinib.Approved
Porfimer sodiumAnvirzel may decrease the cardiotoxic activities of Porfimer.Approved, Investigational
porfiromycinAnvirzel may decrease the cardiotoxic activities of porfiromycin.Investigational
PractololPractolol may increase the bradycardic activities of Anvirzel.Approved
PralatrexateAnvirzel may decrease the cardiotoxic activities of Pralatrexate.Approved
PrednimustineAnvirzel may decrease the cardiotoxic activities of Prednimustine.Investigational
PrednisoloneAnvirzel may decrease the cardiotoxic activities of Prednisolone.Approved, Vet Approved
PrednisoneAnvirzel may decrease the cardiotoxic activities of Prednisone.Approved, Vet Approved
PrimaquineThe serum concentration of Anvirzel can be increased when it is combined with Primaquine.Approved
ProcarbazineAnvirzel may decrease the cardiotoxic activities of Procarbazine.Approved
PropafenoneThe serum concentration of Anvirzel can be increased when it is combined with Propafenone.Approved
PropranololPropranolol may increase the bradycardic activities of Anvirzel.Approved, Investigational
PropylthiouracilThe serum concentration of Anvirzel can be increased when it is combined with Propylthiouracil.Approved
PuromycinAnvirzel may decrease the cardiotoxic activities of Puromycin.Experimental
PyrantelPyrantel may increase the arrhythmogenic activities of Anvirzel.Approved, Vet Approved
PyrazoloacridineAnvirzel may decrease the cardiotoxic activities of Pyrazoloacridine.Investigational
QuinacrineAnvirzel may decrease the cardiotoxic activities of Quinacrine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Anvirzel.Approved
QuinidineThe serum concentration of Anvirzel can be increased when it is combined with Quinidine.Approved
Radium Ra 223 DichlorideAnvirzel may decrease the cardiotoxic activities of Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedAnvirzel may decrease the cardiotoxic activities of Raltitrexed.Approved, Investigational
RamucirumabAnvirzel may decrease the cardiotoxic activities of Ramucirumab.Approved, Investigational
RanibizumabAnvirzel may decrease the cardiotoxic activities of Ranibizumab.Approved
RanpirnaseAnvirzel may decrease the cardiotoxic activities of Ranpirnase.Investigational
RapacuroniumRapacuronium may increase the arrhythmogenic activities of Anvirzel.Withdrawn
RegorafenibAnvirzel may decrease the cardiotoxic activities of Regorafenib.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Anvirzel.Approved
ResveratrolAnvirzel may decrease the cardiotoxic activities of Resveratrol.Experimental, Investigational
Rhodamine 6GAnvirzel may decrease the cardiotoxic activities of Rhodamine 6G.Experimental
RibostamycinThe serum concentration of Anvirzel can be decreased when it is combined with Ribostamycin.Approved
RituximabAnvirzel may decrease the cardiotoxic activities of Rituximab.Approved
RocuroniumRocuronium may increase the arrhythmogenic activities of Anvirzel.Approved
RomidepsinAnvirzel may decrease the cardiotoxic activities of Romidepsin.Approved, Investigational
RomiplostimAnvirzel may decrease the cardiotoxic activities of Romiplostim.Approved
RoquinimexAnvirzel may decrease the cardiotoxic activities of Roquinimex.Investigational
RubitecanAnvirzel may decrease the cardiotoxic activities of Rubitecan.Investigational
RucaparibAnvirzel may decrease the cardiotoxic activities of Rucaparib.Approved, Investigational
RuxolitinibAnvirzel may decrease the cardiotoxic activities of Ruxolitinib.Approved
SalirasibAnvirzel may decrease the cardiotoxic activities of Salirasib.Investigational
SaracatinibAnvirzel may decrease the cardiotoxic activities of Saracatinib.Investigational
SatraplatinAnvirzel may decrease the cardiotoxic activities of Satraplatin.Investigational
SeliciclibAnvirzel may decrease the cardiotoxic activities of Seliciclib.Investigational
SemaxanibAnvirzel may decrease the cardiotoxic activities of Semaxanib.Investigational
SeocalcitolAnvirzel may decrease the cardiotoxic activities of Seocalcitol.Experimental
SiltuximabAnvirzel may decrease the cardiotoxic activities of Siltuximab.Approved
SirolimusAnvirzel may decrease the cardiotoxic activities of Sirolimus.Approved, Investigational
SisomicinThe serum concentration of Anvirzel can be decreased when it is combined with Sisomicin.Investigational
SizofiranAnvirzel may decrease the cardiotoxic activities of Sonifilan.Investigational
SolithromycinThe serum concentration of Anvirzel can be increased when it is combined with Solithromycin.Investigational
SonidegibAnvirzel may decrease the cardiotoxic activities of Sonidegib.Approved, Investigational
SorafenibAnvirzel may decrease the cardiotoxic activities of Sorafenib.Approved, Investigational
SotalolSotalol may increase the bradycardic activities of Anvirzel.Approved
SP1049CThe serum concentration of Anvirzel can be decreased when it is combined with SP1049C.Investigational
SparfloxacinAnvirzel may decrease the cardiotoxic activities of Sparfloxacin.Approved
Sparfosic acidAnvirzel may decrease the cardiotoxic activities of Sparfosic acid.Experimental
SparsomycinAnvirzel may decrease the cardiotoxic activities of Sparsomycin.Experimental
SpectinomycinThe serum concentration of Anvirzel can be decreased when it is combined with Spectinomycin.Approved, Vet Approved
SpiramycinThe serum concentration of Anvirzel can be increased when it is combined with Spiramycin.Approved
SpironolactoneThe therapeutic efficacy of Anvirzel can be decreased when used in combination with Spironolactone.Approved
squalamineAnvirzel may decrease the cardiotoxic activities of squalamine.Investigational
SRT501Anvirzel may decrease the cardiotoxic activities of SRT501.Investigational
StreptomycinThe serum concentration of Anvirzel can be decreased when it is combined with Streptomycin.Approved, Vet Approved
StreptozocinAnvirzel may decrease the cardiotoxic activities of Streptozocin.Approved
SuccinylcholineSuccinylcholine may increase the arrhythmogenic activities of Anvirzel.Approved
SulfasalazineThe serum concentration of Anvirzel can be decreased when it is combined with Sulfasalazine.Approved
SulforaphaneAnvirzel may decrease the cardiotoxic activities of Sulforaphane.Investigational
SulindacAnvirzel may decrease the cardiotoxic activities of Sulindac.Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Anvirzel.Approved
SunitinibAnvirzel may decrease the cardiotoxic activities of Sunitinib.Approved, Investigational
SuraminAnvirzel may decrease the cardiotoxic activities of Suramin.Approved
TalaporfinAnvirzel may decrease the cardiotoxic activities of Talaporfin.Investigational
TalazoparibAnvirzel may decrease the cardiotoxic activities of Bmn 673.Investigational
TamoxifenAnvirzel may decrease the cardiotoxic activities of Tamoxifen.Approved
TegafurAnvirzel may decrease the cardiotoxic activities of Tegafur.Approved
TelithromycinThe serum concentration of Anvirzel can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Anvirzel can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinAnvirzel may decrease the cardiotoxic activities of Temafloxacin.Withdrawn
TemoporfinAnvirzel may decrease the cardiotoxic activities of Temoporfin.Approved
TemozolomideAnvirzel may decrease the cardiotoxic activities of Temozolomide.Approved, Investigational
TemsirolimusAnvirzel may decrease the cardiotoxic activities of Temsirolimus.Approved
TeniposideAnvirzel may decrease the cardiotoxic activities of Teniposide.Approved
TestolactoneAnvirzel may decrease the cardiotoxic activities of Testolactone.Approved
TezacitabineAnvirzel may decrease the cardiotoxic activities of Tezacitabine.Investigational
ThalidomideAnvirzel may decrease the cardiotoxic activities of Thalidomide.Approved, Investigational, Withdrawn
ThiotepaAnvirzel may decrease the cardiotoxic activities of Thiotepa.Approved
ThymalfasinAnvirzel may decrease the cardiotoxic activities of Thymalfasin.Approved, Investigational
TiboloneAnvirzel may decrease the cardiotoxic activities of Tibolone.Approved
TimololTimolol may increase the bradycardic activities of Anvirzel.Approved
TioguanineAnvirzel may decrease the cardiotoxic activities of Tioguanine.Approved
Tiomolibdate ionAnvirzel may decrease the cardiotoxic activities of Tetrathiomolybdate.Investigational
TipifarnibAnvirzel may decrease the cardiotoxic activities of Tipifarnib.Investigational
TirapazamineAnvirzel may decrease the cardiotoxic activities of Tirapazamine.Investigational
TivozanibAnvirzel may decrease the cardiotoxic activities of Tivozanib.Investigational
TobramycinThe serum concentration of Anvirzel can be decreased when it is combined with Tobramycin.Approved, Investigational
TolevamerThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Anvirzel.Approved
TopotecanAnvirzel may decrease the cardiotoxic activities of Topotecan.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Anvirzel.Approved
ToremifeneAnvirzel may decrease the cardiotoxic activities of Toremifene.Approved, Investigational
TositumomabAnvirzel may decrease the cardiotoxic activities of Tositumomab.Approved
TrabectedinAnvirzel may decrease the cardiotoxic activities of Trabectedin.Approved, Investigational
TrametinibAnvirzel may decrease the cardiotoxic activities of Trametinib.Approved
TrastuzumabAnvirzel may decrease the cardiotoxic activities of Trastuzumab.Approved, Investigational
Trastuzumab emtansineAnvirzel may decrease the cardiotoxic activities of Trastuzumab emtansine.Approved
TrebananibAnvirzel may decrease the cardiotoxic activities of Amg 386.Investigational
TreosulfanAnvirzel may decrease the cardiotoxic activities of Treosulfan.Investigational
TretazicarAnvirzel may decrease the cardiotoxic activities of CB1954.Investigational
TretinoinAnvirzel may decrease the cardiotoxic activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe therapeutic efficacy of Anvirzel can be decreased when used in combination with Triamterene.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Anvirzel.Approved, Vet Approved
TridolgosirAnvirzel may decrease the cardiotoxic activities of Swainsonine.Experimental
TrifluridineAnvirzel may decrease the cardiotoxic activities of Trifluridine.Approved
TrilostaneAnvirzel may decrease the cardiotoxic activities of Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimetrexateAnvirzel may decrease the cardiotoxic activities of Trimetrexate.Approved, Investigational
TriptorelinAnvirzel may decrease the cardiotoxic activities of Triptorelin.Approved, Vet Approved
TrofosfamideAnvirzel may decrease the cardiotoxic activities of Trofosfamide.Investigational
TrovafloxacinAnvirzel may decrease the cardiotoxic activities of Trovafloxacin.Approved, Withdrawn
TroxacitabineAnvirzel may decrease the cardiotoxic activities of Troxacitabine.Investigational
TTNPBAnvirzel may decrease the cardiotoxic activities of TTNPB.Experimental
TubercidinAnvirzel may decrease the cardiotoxic activities of Tubercidin.Experimental
TubocurarineTubocurarine may increase the arrhythmogenic activities of Anvirzel.Approved
TylosinThe serum concentration of Anvirzel can be increased when it is combined with Tylosin.Vet Approved
UbenimexAnvirzel may decrease the cardiotoxic activities of Ubenimex.Experimental
Uracil mustardAnvirzel may decrease the cardiotoxic activities of Uracil mustard.Approved
VadimezanAnvirzel may decrease the cardiotoxic activities of ASA404.Investigational
ValrubicinAnvirzel may decrease the cardiotoxic activities of Valrubicin.Approved
VandetanibAnvirzel may decrease the cardiotoxic activities of Vandetanib.Approved
VapreotideAnvirzel may decrease the cardiotoxic activities of Vapreotide.Approved, Investigational
VecuroniumVecuronium may increase the arrhythmogenic activities of Anvirzel.Approved
VeliparibAnvirzel may decrease the cardiotoxic activities of Veliparib.Investigational
VemurafenibAnvirzel may decrease the cardiotoxic activities of Vemurafenib.Approved
VerapamilVerapamil may increase the atrioventricular blocking (AV block) activities of Anvirzel.Approved
VerteporfinAnvirzel may decrease the cardiotoxic activities of Verteporfin.Approved, Investigational
VesnarinoneAnvirzel may decrease the cardiotoxic activities of Vesnarinone.Investigational
VinblastineAnvirzel may decrease the cardiotoxic activities of Vinblastine.Approved
VincristineAnvirzel may decrease the cardiotoxic activities of Vincristine.Approved, Investigational
VindesineAnvirzel may decrease the cardiotoxic activities of Vindesine.Approved
VinflunineAnvirzel may decrease the cardiotoxic activities of Vinflunine.Approved
VinorelbineAnvirzel may decrease the cardiotoxic activities of Vinorelbine.Approved, Investigational
VismodegibAnvirzel may decrease the cardiotoxic activities of Vismodegib.Approved
Vitamin AAnvirzel may decrease the cardiotoxic activities of Vitamin A.Approved, Nutraceutical, Vet Approved
VorinostatAnvirzel may decrease the cardiotoxic activities of Vorinostat.Approved, Investigational
ZorubicinAnvirzel may decrease the cardiotoxic activities of Zorubicin.Experimental
Zuretinol acetateAnvirzel may decrease the cardiotoxic activities of Qlt091001.Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1WithdrawnTreatmentChemotherapeutic Agent Toxicity / Lung Cancers1
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00299 mg/mLALOGPS
logP2.1ALOGPS
logP2.95ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)6.82ChemAxon
pKa (Strongest Basic)-3.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area120.75 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity148.45 m3·mol-1ChemAxon
Polarizability63.2 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid lactones
Direct ParentCardenolide glycosides and derivatives
Alternative ParentsSteroidal glycosides / Steroid esters / 14-hydroxysteroids / Hexoses / O-glycosyl compounds / Oxanes / Butenolides / Dicarboxylic acids and derivatives / Tertiary alcohols / Enoate esters
SubstituentsCardanolide-glycoside / Steroidal glycoside / Steroid ester / 14-hydroxysteroid / Hydroxysteroid / Hexose monosaccharide / Glycosyl compound / O-glycosyl compound / 2-furanone / Dicarboxylic acid or derivatives
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptorssteroid ester, steroid saponin, 14beta-hydroxy steroid, cardenolide glycoside (CHEBI:59030 )
Drug created on October 20, 2016 18:39 / Updated on September 01, 2017 12:25